Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 1;8(1):41-47.
doi: 10.1001/jamaoncol.2021.5143.

Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening

Michael S Leapman  1   2 , Rong Wang  2   3 , Henry Park  2   4 , James B Yu  2   4 , Preston C Sprenkle  1 , Matthew R Cooperberg  5   6 , Cary P Gross  2   7 , Xiaomei Ma  2   3
Affiliations

Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening

Michael S Leapman et al. JAMA Oncol. .

Abstract

Importance: In April 2017, the US Preventive Services Task Force (USPSTF) published a draft guideline that reversed its 2012 guidance advising against prostate-specific antigen (PSA)-based screening for prostate cancer in all men (grade D), instead endorsing individual decision-making for men aged 55 to 69 years (grade C).

Objective: To evaluate changes in rates of PSA testing after revisions in the USPSTF guideline on prostate cancer screening.

Design, setting, and participants: This retrospective cohort study used deidentified claims data from Blue Cross Blue Shield beneficiaries aged 40 to 89 years from January 1, 2013, through December 31, 2019.

Exposures: Publication of the USPSTF's draft (April 2017) and final (May 2018) recommendation on prostate cancer screening.

Main outcomes and measures: Age-adjusted rates of PSA testing in bimonthly periods were calculated, and PSA testing rates from calendar years before (January 1 to December 31, 2016) and after (January 1 to December 31, 2019) the guideline change were compared. Interrupted time series analyses were used to evaluate the association of the draft (April 2017) and published (May 2018) USPSTF guideline with rates of PSA testing. Changes in rates of PSA testing were further evaluated among beneficiaries within the age categories reflected in the guideline: 40 to 54 years, 55 to 69 years, and 70 to 89 years.

Results: The median number of eligible beneficiaries for each bimonthly period was 8 087 565 (range, 6 407 602-8 747 308), and the median age of all included eligible beneficiaries was 53 years (IQR, 47-59 years). Between 2016 and 2019, the mean (SD) rate of PSA testing increased from 32.5 (1.1) to 36.5 (1.1) tests per 100 person-years, a relative increase of 12.5% (95% CI, 1.1%-24.4%). During the same period, mean (SD) rates of PSA testing increased from 20.6 (0.8) to 22.7 (0.9) tests per 100 person-years among men aged 40 to 54 years (relative increase, 10.1%; 95% CI, -2.8% to 23.7%), from 49.8 (1.9) to 55.8 (1.8) tests per 100 person-years among men aged 55 to 69 years (relative increase, 12.1%; 95% CI, -0.2% to 25.2%), and from 38.0 (1.4) to 44.2 (1.4) tests per 100 person-years among men aged 70 to 89 years (relative increase, 16.2%; 95% CI, 4.2%-29.0%). Interrupted time series analysis revealed a significantly increasing trend of PSA testing after April 2017 among all beneficiaries (0.30 tests per 100 person-years for each bimonthly period; P < .001).

Conclusions and relevance: This large national cohort study found that rates of PSA testing increased after the USPSTF's draft statement in 2017, reversing trends seen after earlier guidance against PSA testing for all patients. Increased testing was also observed among older men, who may be less likely to benefit from prostate cancer screening.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Leapman reported receiving grants from the National Institutes of Health/National Cancer Institute during the conduct of the study. Dr Park reported receiving honoraria from Bristol Myers Squibb and RadOncQuestions LLC. Dr Yu reported serving as a consultant for Boston Scientific and serving on the advisory board for Galera Therapeutics Inc outside the submitted work. Dr Cooperberg reported receiving personal fees from Astellas, Dendreon, AstraZeneca, Exact Sciences, Veracyte, Janssen, Bayer, and Merck outside the submitted work. Dr Gross reported receiving grants from the National Comprehensive Cancer Network, Pfizer/AstraZeneca, and Johnson & Johnson; personal fees from Genentech; and speaking at a scientific conference for Flatiron outside the submitted work. Dr Ma reported receiving grants from Celgene/Bristol Myers Squibb and personal fees from Bristol Myers Squibb outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Prostate-Specific Antigen (PSA) Testing Rates Among Commercially Insured Patients Relative to the April 2017 Publication of US Preventive Services Task Force Draft Guideline That Reversed Prior Guidance Against PSA Testing
The symbols indicate the observed bimonthly testing rates.
See this image and copyright information in PMC

Comment in

References

    1. Moyer VA; U.S. Preventive Services Task Force . Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134. doi:10.7326/0003-4819-157-2-201207170-00459 - DOI - PubMed
    1. Slomski A. USPSTF finds little evidence to support advising PSA screening in any man. JAMA. 2011;306(23):2549-2551. doi:10.1001/jama.2011.1804 - DOI - PubMed
    1. Chou R, Croswell JM, Dana T, et al. . Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(11):762-771. - PubMed
    1. Barocas DA, Mallin K, Graves AJ, et al. . Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States. J Urol. 2015;194(6):1587-1593. doi:10.1016/j.juro.2015.06.075 - DOI - PubMed
    1. Becker DJ, Rude T, Walter D, et al. . The association of veterans’ PSA screening rates with changes in USPSTF recommendations. J Natl Cancer Inst. 2021;113(5):626-631. doi:10.1093/jnci/djaa120 - DOI - PMC - PubMed

Publication types

Substances